Updated on May 28, 2022
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
WEDNESDAY, Sept. 26, 2018 (HealthDay News) -- A combination of two HIV-fighting antibodies can suppress the virus in some patients, even after they stop standard drugs, a preliminary trial has shown.
Researchers found that among 11 HIV patients given the antibody combo, nine maintained complete suppression of the virus after going off their medication regimen. The benefit typically lasted about five months.
The hope, experts said, is that the therapy -- or others like it -- could one day free some patients from taking daily pills to control the AIDS-causing virus.
The drug "cocktails" used to treat HIV -- what doctors call antiretroviral therapy (ART) -- have changed the face of the epidemic in countries where they are widely available.
The drugs can drive HIV down to undetectable levels in the blood, making the disease a manageable chronic condition.
"The current medications are very effective," said Dr. Marina Caskey, one of the researchers on the new work. "They allow people to have long and healthy lives for the most part."
However, she added, treatment is daily and lifelong. The drugs do not banish HIV, and if a patient stops taking them, the virus comes roaring back.
Plus, Caskey noted, the medications carry side effects. Over the long haul, that includes increased risks of heart, kidney and liver disease, diabetes and bone density loss.
So researchers are trying to develop therapies that can send HIV into remission for prolonged periods. With antibody therapy, the vision is to give patients an infusion every three to six months, explained Caskey, an associate professor at Rockefeller University in New York City.
Specifically, research is focusing on "broadly neutralizing antibodies," or bNAbs. That means they neutralize multiple strains of HIV.
Past studies have tested single bNAbs and found the tactic doesn't work for long.
"When you give one, the virus can escape and modify itself to become resistant [to the antibody]," Caskey explained.
She and her colleagues reasoned that a two-pronged antibody attack would be more effective -- much like drug combinations work against the virus.
So they tested a combination of two bNAbs in people described as "elite controllers." They have HIV, but their immune systems are able to control the virus without drugs.
In one study, the researchers treated 11 patients whose HIV was under control with standard medications. Tests had shown that all appeared sensitive to the two antibodies.
The patients stopped their HIV medication. Then, over six weeks, they received three infusions of the antibodies. Overall, the virus remained suppressed in nine patients -- typically for 21 weeks, though two went to at least 30 weeks.
Two of the 11 patients, however, were found to harbor HIV that was resistant to at least one of the antibodies. Their viral levels rose within 12 weeks of stopping their medication.
That is a critical point, said Caskey. People have to be sensitive to the particular antibodies used in the therapy, and not everyone will be.
In a second study, the researchers gave the antibody therapy to four patients who had detectable HIV in their blood. They found the treatment lowered those levels for up to three months.
The studies were published separately Sept. 26 in the journals Nature and Nature Medicine.
Dr. Melanie Thompson is chair of the HIV Medicine Association. She called the new findings "exciting," but also said much work remains.
Larger, longer-term studies are needed to see how often the therapy should be given, and how well it works over time, said Thompson, who was not involved with the new studies.
Practically speaking, Thompson noted, the current testing used to predict patients' sensitivity to the antibodies is fairly complex.
"I think the testing will have to be refined and made more affordable," she said.
As for side effects, Caskey's team said some patients had mild fatigue, but nothing more serious.
"So far," Thompson said, "the safety profile of these antibodies has been excellent."
Caskey pointed to another question for future studies: Can antibody therapies, over time, spur the immune system to produce its own HIV-fighting antibodies, possibly reducing the need for treatment?
"The new frontiers in HIV research involve looking at longer-acting treatments," Thompson said. "Can we have long-term viral suppression with as little drug as possible?"
The current studies were funded by the U.S. National Institutes of Health, the Bill and Melinda Gates Foundation, and other grant programs.
The U.S. National Institute of Allergy and Infectious Diseases has more on HIV treatment.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.